A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).

Recent novel treatments for chronic lymphocytic leukemia (CLL), such as second-generation covalent Bruton tyrosine kinase inhibitors (cBTKis) and venetoclax-obinutuzumab (VenO), may offer better ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic ...

Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.

A study has demonstrated the potential of a novel ligand-based CAR T-cell therapy for targeting CD7-positive T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell ...

Cash: As of March 31, 2025, Cellectis had $246 million in consolidated cash, cash equivalents, restricted cash and fixed-term deposits classified as current-financial assets. The Company believes its ...

The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, ...